As the epidemic continues to claim more victims, and the number of people infected with the Coronavirus reaches 50 million, the world awaits the dawn of the vaccine, which will end the months-long Corona series.
In this context, the CEO renewed For “AstraZeneca” (British and Swedish) company Pharmaceutical giant, he expected it to be Corona candidate vaccine Ready to use at the end of December pending regulatory approval.
Vaccination end December ?!
In an interview with the Swedish newspaper “Dagenz Nyther”, the CEO of the company, Pascal Suriot, said, “The regulatory bodies are constantly working with our data, and if it is fast when we are ready, we can start vaccinating people in January, and maybe the end of December.”
As for the expected profits from this vaccine if approved, he said: Perhaps we will never achieve profits, no one knows how many times a person will need to be vaccinated, because if the vaccine is very effective, and people protect for many years, and the disease disappears, then there is no profitable market!
At the same time, however, he indicated that many experts believe that there will be a periodic need for re-vaccination from time to time, adding: “If this must be done annually, then we can make a profit starting from 2022.” He continued: “But we must make sure that the vaccine works effectively first.”
It is noteworthy that the person responsible for managing the working group on the Covid 19 vaccine trial that the University of Oxford is conducting in conjunction with AstraZeneca, last week, hinted at a very small possibility that the vaccine will be launched before the end of December, indicating that the final results of the vaccine trials will initially appear before the end of this year.
This vaccine was subjected to a setback last month with the death of a Brazilian volunteer in clinical trials, but the British University confirmed that testing the vaccine will continue even after the death of the volunteer, who will investigate his circumstances.
As previously, the final clinical trials were also temporarily stopped at the beginning of last September, after a volunteer fell ill in Britain. AstraZeneca described the matter at that time as a “routine procedure” that takes place in the event that any participant suffers from any “unclear disease”, confirming to follow The results of the experiments are being closely monitored throughout the world.
– .
